What is a toxic dose of montelukast (Singulair)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dangerous Amounts of Montelukast (Singulair)

Montelukast is remarkably safe in overdose, with doses up to 536 mg or 33.71 mg/kg in children producing only minor effects and no serious or life-threatening adverse events. 1

Toxicity Profile of Montelukast

Montelukast is a leukotriene receptor antagonist commonly prescribed for asthma and allergic rhinitis. The evidence strongly suggests it has an excellent safety profile even in significant overdose situations:

Normal Therapeutic Dosing

  • Adults (≥15 years): 10 mg once daily 2, 3
  • Children (6-14 years): 5 mg once daily 2, 3
  • Children (1-5 years): 4 mg once daily 2

Overdose Information

  • In a comprehensive analysis of 17,069 montelukast exposures in children aged 5-17 years:

    • Abdominal pain was the most common adverse event (0.23% overall)
    • Even with ultra-high doses (≥50 mg), abdominal pain occurred in only 1.46% of cases
    • No serious or life-threatening events were reported with doses up to 445 mg 1
  • Another study examining 3,698 pediatric exposures found:

    • 95% of cases resulted in no observed effects
    • Only 5% had minor effects with doses up to 536 mg or 33.71 mg/kg
    • No serious adverse effects were reported 4
  • Case reports document:

    • A 3-year-old child who ingested 80 mg (approximately 8 times the therapeutic dose) with no observed symptoms 5
    • A 5-year-old child who ingested 135 mg with no observed symptoms 5

Clinical Management of Overdose

When to Seek Medical Care

  • Home observation is appropriate for most accidental ingestions 4
  • Healthcare facility evaluation may be considered for:
    • Doses >100 mg (56% of such cases were managed in healthcare facilities)
    • Doses >5 mg/kg (47% of such cases were managed in healthcare facilities) 4

Monitoring Parameters

  • Abdominal discomfort (most common symptom)
  • Gastrointestinal symptoms (nausea, vomiting)
  • No specific antidote is required as serious toxicity is not expected

Special Considerations

Safety in Context

  • Montelukast has demonstrated a tolerability profile similar to placebo in both short-term and long-term administration 6
  • Even doses up to 200 mg per day (20 times the recommended dose) administered for 5 months showed no dose-related adverse effects in adults 6

Potential Pitfalls

  • Don't confuse montelukast with other medications that may have significant toxicity in overdose
  • The excellent safety profile of montelukast should not lead to complacency about medication safety in general
  • While montelukast itself appears quite safe in overdose, always consider the possibility of co-ingestions with other medications that may be more toxic

In conclusion, montelukast demonstrates an exceptional safety profile even in significant overdose situations, with minimal clinical effects reported at doses many times the therapeutic recommendation.

References

Research

Adverse events are rare after single-dose montelukast exposures in children.

Clinical toxicology (Philadelphia, Pa.), 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pediatric montelukast ingestions reported to Texas poison control centers, 2000-2005.

Journal of toxicology and environmental health. Part A, 2007

Research

Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.